초록

This invention relates to methods of using a Listeria vaccine vector to induce a Th1 immune response in subjects having persistent Th2 immune response profiles.

대표청구항 ▼

1. A method of inducing a Th1 immune response in a subject having a parasitic infection, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein the Listeria vaccine vector expresses and secretes an antigen fused to an ad

1. A method of inducing a Th1 immune response in a subject having a parasitic infection, the method comprising the step of administering to said subject a therapeutically effective dose of a Listeria vaccine vector, wherein the Listeria vaccine vector expresses and secretes an antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, wherein said antigen is an infectious disease antigen, and wherein said administering produces a Th1 cell-mediated immune response in said parasite infected subject. 2. The method of claim 1, wherein said additional polypeptide is a Listeriolysin O (LLO) polypeptide, an ActA polypeptide, or a PEST sequence. 3. The method of claim 1, wherein said subject is human. 4. The method of claim 1, wherein said antigen is an HIV antigen, a malaria antigen, or a tuberculosis antigen. 5. The method of claim 4, wherein said antigen elicits an immune response to HIV-1 gag cytotoxic T lymphocyte or to HIV-1 gag T helper epitopes. 6. The method of claim 1, wherein said parasite is a helminth, or a protozoan parasite. 7. The method of claim 6 wherein said helminth is Schistosoma mansoni. 8. The method of claim 6, wherein said protozoan parasite is malaria, leishmania, toxoplasma. 9. The method of claim 1, further comprising the step of administering a booster vaccination. 10. The method of claim 9, wherein said booster vaccination comprises a DNA vaccine encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a recombinant polypeptide comprising said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof, a viral vector encoding said antigen fused to an additional immunogenic polypeptide or a signal sequence thereof or a live recombinant Listeria vaccine vector. 11. The method of claim 1, wherein said response is a therapeutic immune response or a prophylactic immune response. 12. The method of claim 1, wherein said response is a cytotoxic T-cell response or a memory T-cell response. 13. The method of claim 1, wherein said Listeria vaccine vector is a recombinant auxotrophic dal/dat mutant Listeria strain. 14. The method of claim 1, wherein said immune response is against an infectious disease in said subject. 15. The method of claim 14, wherein said infectious disease is amebiasis, an HIV infection, a malaria infection, a leishmania infection, a trichuris infection, or a tuberculosis infection. 16. The method of claim 14, wherein said immune response against said infectious disease results in treatment, suppression, or inhibition of said infectious disease.